Cited 0 times in
Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김민환 | - |
dc.date.accessioned | 2015-12-24T09:02:05Z | - |
dc.date.available | 2015-12-24T09:02:05Z | - |
dc.date.issued | 2014 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/134806 | - |
dc.description | Dept. of Medicine/석사 | - |
dc.description.abstract | The aim of this study is to evaluate the prevalence and prognostic significance of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) rearrangement in never-smokers with surgically resected lung adenocarcinoma. We enrolled 162 consecutive never-smokers who underwent curative resection for stage IB to IIIA lung adenocarcinoma. We concurrently analyzed mutations in the epidermal growth factor receptor (EGFR) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) genes, and investigated ALK rearrangements by fluorescence in situ hybridization assay. ROS1 rearrangement was also determined in all triple (EGFR/KRAS/ALK)-negative tumors. Of 162 never smokers with lung adenocarcinoma, 14 (8.6%) and 5 (3.1%) had ALK and ROS1 rearrangements, respectively. Nineteen of the 74 (25.7%) EGFR and KRAS mutation-negative patients were fusion-positive (ALK or ROS1 fusion). Fusion-positive patients tended to have shorter median disease-free survival (DFS) than fusion-negative patients (28.0 vs. 33.9 months; p = 0.128). In multivariate analysis, fusion-positive patients had significantly poorer DFS than fusion-negative patients after adjustment for age, sex, T stage, lymph node metastasis, and adjuvant chemotherapy use (p = 0.022; hazard ratio, 2.11; 95% confidence interval, 1.19-4.30). The difference in DFS between fusion-positive and fusion-negative patients was more prominent among patients with stage IB to IIB tumors (20.7 vs. 38.2 months; p = 0.046). Pleural (38.5% vs. 23.9%) and extrathoracic distant (46.2% vs. 35.8%) metastasis rates at the first recurrence were higher in fusion-positive patients. This study shows significantly poorer DFS of ALK or ROS1 fusion-positive lung adenocarcinoma in never-smokers after curative surgery. | - |
dc.description.statementOfResponsibility | open | - |
dc.publisher | Graduate School, Yonsei University | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma | - |
dc.title.alternative | 수술적 절제를 받은 비흡연자, 폐선암 환자에서의 anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1) 전위의 임상적, 예후적 의미 | - |
dc.type | Thesis | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.localId | A00482 | - |
dc.contributor.alternativeName | Kim, Min Hwan | - |
dc.contributor.affiliatedAuthor | 김민환 | - |
dc.type.local | Thesis | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.